View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 15, 2022

Moderna reports dosing of first subject in Phase I HIV trimer vaccine trial

The trial will analyse the safety and immunogenicity of the vaccines in nearly 100 HIV-negative adults of the age 18 to 55 years.

Moderna has reported the dosing of the first subject in a Phase I HVTN 302 clinical trial of an investigational human immunodeficiency virus (HIV) trimer messenger ribonucleic acid (mRNA) vaccine, mRNA-1574.

The Division of AIDS (DAIDS) of the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) is sponsoring and funding the trial. 

The multicentre, open-label, randomised trial will analyse the safety and immunogenicity of the vaccines by enrolling nearly 100 HIV-negative adults of the age 18 to 55 years.

Scripps Research was awarded NIAID (DAIDS) Consortium for HIV/AIDS Vaccine Development (CHAVD) funding to develop native-like HIV trimers and produce the mRNA-1574 vaccine.

The company anticipates the soluble and membrane-bound HIV envelope trimer mRNA vaccines to be safe and well-tolerated in people who are not HIV infected and induce autologous neutralising antibodies.

Moderna president Stephen Hoge said: “Developing a vaccine regimen that induces sustained protective levels of HIV neutralising antibodies in humans has been difficult to achieve. 

“With the launch of our second HIV vaccine trial, we are advancing our strategy to utilise multiple mRNA encoded native-like HIV trimers and leverage the power of our mRNA platform to accelerate the discovery of a protective HIV vaccine. 

“This study is another step in our fight against HIV, as well as other latent viruses such as our recently launched studies in CMV and EBV.”

Currently, the company is progressing two HIV preventative vaccine approaches based on germline targeting and immune-focusing techniques. 

Apart from the mRNA-1574 vaccine trial, Moderna is collaborating on HIV vaccine antigens, mRNA-1644 and mRNA-1644v2-Core. 

These HIV vaccine antigens are being assessed in an IAVI-sponsored Phase I trial, which is supported by the Bill & Melinda Gates Foundation.

The latest development comes after the company dosed the first subject in Phase II trial of its Omicron-specific bivalent booster candidate, mRNA-1273.214.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy